Promise for Patients

We are at the leading edge of antibody-drug conjugate (ADC) research and their use in the treatment of cancer. ADCs harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. This innovative approach to therapy offers meaningful efficacy while minimizing side effects.

We are committed to transforming extraordinary scientific advances into safe and effective solutions for people with cancer. We conduct rigorous research and development in areas of serious unmet medical need, with a focus on developing:

  • Novel antibodies and other targeting agents
  • New classes of stable linkers
  • Potent cell-killing agents to attach to targeting molecules
  • Novel antibody engineering technologies
Dr. Peter Senter
Vice President Chemistry and Sr. Distinguished Fellow
"Our creative research allows us to bring ideas to life that will improve outcomes for cancer patients. We focus on being bold and hopeful, always inspired by patients throughout the innovation process."


During more than 20 years of research and innovation, we have developed a diverse suite of ADC technologies and are driving the field to improve outcomes for patients with hematologic and solid tumors. Our technology empowers more than 20 of the ADCs in clinical development across the industry, including both proprietary and collaborator programs.